Brief: Aptinyx Initiates Phase 2B Study Of NYX-783 In Patients With Post-Traumatic Stress Disorder
16/12/2021 12:43
Dec 16 (Reuters) - Aptinyx Inc APTX.O :
* APTINYX INITIATES PHASE 2B STUDY OF NYX-783 IN PATIENTS
WITH
POST-TRAUMATIC STRESS DISORDER
* APTINYX INC - ANTICIPATES REPORTING DATA FROM PHASE 2B
STUDY IN
SECOND HALF OF 2023
Source text for Eikon: ID:nBwbDjvnNa
Further company coverage: APTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aptinyx
See all newsBrief: Aptinyx Gets Notice Of Delisting Or Failure To Satisfy Continued Listing Rule From Nasdaq
Brief: Aptinyx Inc reports On May 4, Board Deemed It In Best Interests Of Co And Its Stockholders That Co Be Dissolved
Aptinyx Inc reports results for the quarter ended in December - Earnings Summary
Brief: Aptinyx Inc Reports Quarterly Loss Per Share Of $0.18
Aptinyx Inc expected to post a loss of 19 cents a share - Earnings Preview